Cedric Francois Sells 5,000 Shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) Stock

Apellis Pharmaceuticals Inc (NASDAQ:APLS) CEO Cedric Francois sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $30.96, for a total transaction of $154,800.00.

Cedric Francois also recently made the following trade(s):

  • On Thursday, August 20th, Cedric Francois sold 3,457 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $30.00, for a total transaction of $103,710.00.
  • On Tuesday, August 18th, Cedric Francois sold 1,543 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $30.00, for a total transaction of $46,290.00.
  • On Wednesday, July 15th, Cedric Francois sold 5,000 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $32.12, for a total transaction of $160,600.00.

NASDAQ APLS traded up $0.31 on Wednesday, hitting $31.51. 398,242 shares of the company’s stock traded hands, compared to its average volume of 1,075,606. The firm’s 50-day moving average price is $28.61 and its two-hundred day moving average price is $30.55. The firm has a market capitalization of $2.38 billion, a PE ratio of -4.68 and a beta of 1.14. The company has a current ratio of 14.72, a quick ratio of 14.72 and a debt-to-equity ratio of 1.55. Apellis Pharmaceuticals Inc has a 1-year low of $16.85 and a 1-year high of $45.04.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Friday, July 31st. The company reported ($1.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.34) by ($0.23). On average, research analysts anticipate that Apellis Pharmaceuticals Inc will post -6.83 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its holdings in Apellis Pharmaceuticals by 140.2% in the first quarter. Wellington Management Group LLP now owns 10,371,998 shares of the company’s stock valued at $277,866,000 after acquiring an additional 6,054,734 shares during the period. Vanguard Group Inc. boosted its position in Apellis Pharmaceuticals by 44.7% during the second quarter. Vanguard Group Inc. now owns 4,388,181 shares of the company’s stock worth $143,318,000 after purchasing an additional 1,354,710 shares in the last quarter. BlackRock Inc. boosted its position in Apellis Pharmaceuticals by 22.3% during the first quarter. BlackRock Inc. now owns 5,816,260 shares of the company’s stock worth $155,818,000 after purchasing an additional 1,058,755 shares in the last quarter. Candriam Luxembourg S.C.A. increased its position in shares of Apellis Pharmaceuticals by 208.6% in the second quarter. Candriam Luxembourg S.C.A. now owns 1,210,398 shares of the company’s stock valued at $39,533,000 after buying an additional 818,198 shares in the last quarter. Finally, Two Sigma Advisers LP raised its stake in shares of Apellis Pharmaceuticals by 237.4% during the 1st quarter. Two Sigma Advisers LP now owns 877,200 shares of the company’s stock worth $23,500,000 after buying an additional 617,200 shares during the period. Institutional investors and hedge funds own 80.80% of the company’s stock.

Several research firms have issued reports on APLS. JPMorgan Chase & Co. lifted their price target on shares of Apellis Pharmaceuticals from $54.00 to $56.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Oppenheimer reaffirmed a “buy” rating and set a $62.00 target price on shares of Apellis Pharmaceuticals in a research report on Friday, June 12th. UBS Group began coverage on Apellis Pharmaceuticals in a research note on Thursday, May 28th. They issued an “add” rating for the company. BidaskClub lowered Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 31st. Finally, Roth Capital began coverage on shares of Apellis Pharmaceuticals in a research report on Monday, July 20th. They issued a “buy” rating and a $50.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Apellis Pharmaceuticals presently has an average rating of “Buy” and an average target price of $50.14.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.

Read More: Options Trading – What is a Straddle?

Insider Buying and Selling by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.